Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
OPGEN INC (OPGN) Stock Price & Overview
NASDAQ:OPGN • US68373L5057
Current stock price
1.96 USD
-0.34 (-14.78%)
At close:
1.85 USD
-0.11 (-5.61%)
After Hours:
The current stock price of OPGN is 1.96 USD. Today OPGN is down by -14.78%. In the past month the price decreased by -34.88%. In the past year, price increased by 14.62%.
OPGN Key Statistics
52-Week Range1.65 - 38.4
Current OPGN stock price positioned within its 52-week range.
1-Month Range1.8701 - 3.1
Current OPGN stock price positioned within its 1-month range.
- Market Cap
- 2.646M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -28.18
- Dividend Yield
- N/A
OPGN Stock Performance
Today
-14.78%
1 Week
-9.05%
1 Month
-34.88%
3 Months
-40.61%
Longer-term
6 Months -53.77%
1 Year +14.62%
2 Years -97.90%
3 Years -99.69%
5 Years -99.87%
10 Years N/A
OPGN Stock Chart
OPGN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OPGN. When comparing the yearly performance of all stocks, OPGN is a bad performer in the overall market: 79.91% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
OPGN Earnings
Next Earnings DateNov 12, 2024
Last Earnings DateAug 8, 2024
PeriodQ1 / 2024
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise -72.52%
OPGN Forecast & Estimates
6 analysts have analysed OPGN and the average price target is 3.06 USD. This implies a price increase of 56.12% is expected in the next year compared to the current price of 1.96.
For the next year, analysts expect an EPS growth of 99.72% and a revenue growth -0.26% for OPGN
Analysts
Analysts43.33
Price Target3.06 (56.12%)
EPS Next Y99.72%
Revenue Next Year-0.26%
OPGN Financial Highlights
Over the last trailing twelve months OPGN reported a non-GAAP Earnings per Share(EPS) of -28.18. The EPS increased by 79.19% compared to the year before.
Income Statements
Revenue(TTM)2.67M
Net Income(TTM)-26.66M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -897.5% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%101.64%
Sales Q2Q%-81.52%
EPS 1Y (TTM)79.19%
Revenue 1Y (TTM)-12.39%
OPGN Ownership
Ownership
Inst Owners1.19%
Shares1.35M
Float1.28M
Ins Owners1035.79%
Short Float %N/A
Short RatioN/A
OPGN Industry Overview
OPGN operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.6
- Average Fwd P/E
- 22.2
- Average Debt/Equity
- 2.2
OPGN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.91 | 360.632B | ||
| AMGN | AMGEN INC | 15.2 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.05 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.74 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.05 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.56 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 25.03B | ||
| INCY | INCYTE CORP | 10.71 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OPGN
Company Profile
OpGen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland. The company went IPO on 2015-05-05. OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The firm distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The firm's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.
Company Info
IPO: 2015-05-05
OPGEN INC
9717 Key West Avenue, Suite 100
Rockville MARYLAND 20878 US
CEO: Oliver Schacht
Employees: 100
Phone: 13018699683
OPGEN INC / OPGN FAQ
What does OPGN do?
OpGen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland. The company went IPO on 2015-05-05. OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The firm distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The firm's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.
Can you provide the latest stock price for OPGEN INC?
The current stock price of OPGN is 1.96 USD. The price decreased by -14.78% in the last trading session.
Does OPGEN INC pay dividends?
OPGN does not pay a dividend.
What is the ChartMill rating of OPGEN INC stock?
OPGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the Price/Earnings (PE) ratio of OPGEN INC (OPGN)?
OPGEN INC (OPGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-28.18).
Can you provide the market cap for OPGEN INC?
OPGEN INC (OPGN) has a market capitalization of 2.65M USD. This makes OPGN a Nano Cap stock.
Who owns OPGEN INC?
You can find the ownership structure of OPGEN INC (OPGN) on the Ownership tab.